NKG2D-ligands, expressed as both transmembrane proteins and GPI-APs, were released from the PMs of malignant placental, ovarian and prostate cancer cells by incorporation into exosomes [278,279] with resulting impairment of effective NKG2D-dependent immune responses. Here, KLRK1 is linked to prostate carcinoma.